Analyst Price Targets — SRPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 9, 2026 11:14 am | — | Piper Sandler | $20.00 | $20.21 | TheFly | Sarepta price target lowered to $20 from $23 at Piper Sandler |
| July 8, 2026 9:07 pm | — | Wolfe Research | $27.00 | $20.21 | TheFly | Sarepta upgraded to Outperform from Peer Perform at Wolfe Research |
| May 15, 2026 12:25 pm | — | Evercore ISI | $19.00 | $18.20 | TheFly | Sarepta price target lowered to $19 from $20 at Evercore ISI |
| March 26, 2026 12:39 pm | — | Deutsche Bank | $14.00 | $21.68 | TheFly | Deutsche ups Sarepta target, says 35% stock rally overdone |
| March 26, 2026 12:30 pm | — | Wedbush | $35.00 | $21.68 | TheFly | Sarepta price target raised to $35 from $29 at Wedbush |
| March 12, 2026 9:06 pm | Uy Ear | Mizuho Securities | $31.00 | $17.04 | StreetInsider | Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho |
| March 3, 2026 8:44 pm | Ilya Zubkov | Loop Capital Markets | $25.00 | $15.87 | StreetInsider | Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets |
| March 3, 2026 5:00 pm | Andrew Tsai | Jefferies | $30.00 | $15.98 | StreetInsider | Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story" |
| January 27, 2026 12:18 pm | — | Robert W. Baird | $22.00 | $22.80 | TheFly | Sarepta price target raised to $22 from $15 at Baird |
| December 9, 2025 11:46 am | — | Wedbush | $32.00 | $21.86 | TheFly | Wedbush bullish on Sarepta, initiates with an Outperform |
Latest News for SRPT
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against certain of its officers and directors for alleged breaches of fiduciary duty.
Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter…
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:SRPT) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) into traditional approvals for Duchenne muscular dystrophy (DMD).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRPT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.